ONTX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Notice: This stock is marked as potentially delisted. It may not be actively trading.

Insider Ownership Percentage: 3.30%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $0.00

Onconova Therapeutics Insider Trading History Chart

Onconova Therapeutics Share Price & Price History

^$0.00

+0.30 (1.20%)

As of 04/3/2024 12:59 AM ET

Musk’s new company could top a trillion?

From Paradigm Press | Ad

The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840.

Click here to see the details because there’s not much time to prepare.

Onconova Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
1/28/2022	Abraham N Oler	SVP	Buy	1,500	$1.67	$2,505.00
1/21/2022	Abraham N Oler	SVP	Buy	1,500	$2.02	$3,030.00
1/14/2022	Abraham N Oler	SVP	Buy	1,500	$2.20	$3,300.00
1/7/2022	Abraham N Oler	SVP	Buy	1,500	$2.39	$3,585.00

Musk’s new company could top a trillion?

From Paradigm Press | Ad

The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840.

Click here to see the details because there’s not much time to prepare.

SEC Filings (Institutional Ownership Changes) for Onconova Therapeutics (NASDAQ:ONTX)

7.95% of Onconova Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Onconova Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/14/2022	GSA Capital Partners LLP	57,799	$0.15M	0.0%	-76.0%	0.278%
12/29/2021	Hudson Bay Capital Management LP	165,684	$0.64M	0.0%	N/A	0.797%
11/16/2021	CVI Holdings LLC	128,604	$0.49M	0.0%	N/A	0.619%
11/15/2021	Pura Vida Investments LLC	150,000	$0.58M	0.0%	N/A	0.722%
11/15/2021	GSA Capital Partners LLP	240,658	$0.92M	0.1%	N/A	1.158%
8/25/2021	Marshall Wace LLP	24,345	$0.17M	0.0%	N/A	0.154%
8/18/2021	Ikarian Capital LLC	23,226	$0.16M	0.0%	-98.0%	0.147%
8/17/2021	Beacon Pointe Advisors LLC	23,987	$0.17M	0.0%	-90.8%	0.152%
8/16/2021	State Street Corp	115,090	$0.80M	0.0%	+23.9%	0.729%
8/16/2021	Marshall Wace LLP	24,345	$0.17M	0.0%	N/A	0.154%
8/13/2021	Northern Trust Corp	32,298	$0.22M	0.0%	-92.2%	0.205%
8/13/2021	Jump Financial LLC	18,500	$0.13M	0.0%	N/A	0.117%
8/13/2021	Geode Capital Management LLC	142,980	$0.99M	0.0%	-93.1%	0.906%
8/13/2021	Vanguard Group Inc.	680,618	$4.72M	0.0%	-93.5%	4.313%
8/12/2021	Dimensional Fund Advisors LP	73,387	$0.51M	0.0%	N/A	0.465%
8/11/2021	Edmond DE Rothschild Holding S.A.	6,666	$46K	0.0%	-93.3%	0.042%
8/11/2021	Deutsche Bank AG	16,359	$0.11M	0.0%	N/A	0.104%
8/11/2021	Susquehanna Fundamental Investments LLC	24,930	$0.17M	0.0%	N/A	0.158%
8/3/2021	Hillcrest Wealth Advisors NY LLC	16,704	$0.12M	0.1%	-93.3%	0.106%
5/24/2021	Principal Financial Group Inc.	1,258,392	$1.26M	0.0%	+8.3%	7.970%
5/21/2021	Citadel Advisors LLC	58,050	$58K	0.0%	-89.8%	0.025%
5/19/2021	Virtu Financial LLC	837,144	$0.84M	0.1%	+72.7%	0.354%
5/19/2021	MONECO Advisors LLC	30,000	$30K	0.0%	-50.0%	0.013%
5/19/2021	Squarepoint Ops LLC	680,498	$0.68M	0.0%	+179.3%	0.288%
5/18/2021	Millennium Management LLC	2,825,363	$2.82M	0.0%	N/A	1.194%
5/18/2021	Voloridge Investment Management LLC	36,518	$36K	0.0%	N/A	0.015%
5/18/2021	Caxton Associates LP	56,834	$57K	0.0%	N/A	0.024%
5/18/2021	Alyeska Investment Group L.P.	665,795	$0.67M	0.0%	N/A	0.281%
5/18/2021	Citadel Advisors LLC	58,050	$58K	0.0%	-89.8%	0.025%
5/18/2021	Beacon Pointe Advisors LLC	262,005	$0.26M	0.0%	-12.9%	0.111%
5/17/2021	Edmond DE Rothschild Holding S.A.	100,000	$100K	0.0%	N/A	0.042%
5/17/2021	HRT Financial LP	664,608	$0.66M	0.0%	+1,209.2%	0.281%
5/17/2021	Ikarian Capital LLC	1,145,426	$1.14M	0.0%	N/A	0.484%
5/13/2021	Barclays PLC	64,775	$65K	0.0%	+6,377.5%	0.027%
5/13/2021	Renaissance Technologies LLC	3,697,100	$3.69M	0.0%	N/A	1.563%
5/13/2021	Bank of New York Mellon Corp	112,526	$0.11M	0.0%	+192.4%	0.048%
5/12/2021	Northern Trust Corp	414,339	$0.41M	0.0%	+52.0%	0.175%
5/12/2021	Geode Capital Management LLC	2,066,627	$2.06M	0.0%	+60.4%	0.873%
5/12/2021	Moors & Cabot Inc.	65,000	$65K	0.0%	N/A	0.027%
5/12/2021	Granite Point Capital Management L.P.	300,000	$0.30M	0.0%	N/A	0.127%
5/10/2021	Principal Financial Group Inc.	1,258,392	$1.26M	0.0%	+8.3%	0.532%
5/7/2021	BlackRock Inc.	4,472,830	$4.47M	0.0%	+411.3%	1.890%
2/24/2021	Virtu Financial LLC	484,832	$0.23M	0.0%	+9.7%	0.235%
2/23/2021	Principal Financial Group Inc.	1,162,412	$0.54M	0.0%	N/A	0.562%
2/16/2021	Squarepoint Ops LLC	243,647	$0.11M	0.0%	-26.4%	0.118%
2/12/2021	Beacon Pointe Advisors LLC	300,783	$0.14M	0.0%	-11.7%	0.146%
2/4/2021	GSA Capital Partners LLP	227,932	$0.11M	0.0%	N/A	0.110%
1/22/2021	MONECO Advisors LLC	60,000	$41K	0.0%	N/A	0.029%
12/11/2020	Virtu Financial LLC	442,151	$0.12M	0.0%	N/A	0.239%
11/17/2020	Jane Street Group LLC	114,536	$32K	0.0%	+129.0%	0.064%
11/16/2020	Squarepoint Ops LLC	331,039	$93K	0.0%	+3,020.1%	0.184%

Data available starting January 2016

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.